President Donald Trump announced a second drug-pricing deal, this time with AstraZeneca, after hosting CEO Pascal Soriot at the White House. Trump touted steep consumer discounts — even claiming reductions “way over a hundred percent,” including 654 percent off asthma inhalers — and said AstraZeneca will join the planned TrumpRx direct-to-consumer site. The agreement follows Pfizer’s and comes amid Trump’s threats of 100 percent tariffs on pharmaceutical companies. AstraZeneca secured a three-year tariff reprieve while pledging $50bn in U.S. investment and a new Virginia manufacturing center, as officials lauded tariffs as negotiating leverage.

Prepared by Christopher Adams and reviewed by editorial team.